Could space be the key to better, faster drug development?
In this episode of In-Orbit, host Dallas Campbell explores how microgravity environments are reshaping the future of pharmaceuticals. With guests Dr Martin Braddock from GENIXICONSULTING and William Birch from the Satellite Applications Catapult, the discussion dives into why the absence of gravity enables better crystal growth, enhances drug discovery, and opens new possibilities for biomanufacturing in space. The episode unpacks both the science and commercial potential of conducting pharmaceutical R&D off-planet, from creating more effective drugs to future ambitions like 3D bioprinting human tissue in orbit.
The conversation doesn’t shy away from the challenges — including cost, regulatory barriers, and the need for new infrastructure. Whether you're a pharmaceutical innovator, space enthusiast, or curious about the intersection of health and space, this episode offers a fascinating glimpse into how drug development could be transformed in the next decade.
William Birch: Strategic Account Director for Space at the Satellite Applications Catapult, where he connects industry players to drive R&D and economic growth in the UK space sector. Formerly worked in biomedical corporate finance with a focus on longevity research.
Satellite Applications Catapult: LinkedIn, Twitter/X, Facebook, Website
